Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/67559

TítuloP-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study
Autor(es)Sousa, Bárbara
Paredes, Joana
Milanezi, Fernanda
Lopes, Nair
Martins, Diana
Dufloth, Rozany
Vieira, Daniella
Albergaria, André
Veronese, Luiz
Carneiro, Vitor
Carvalho, Sílvia
Costa, José Luis
Zeferino, Luiz
Schmitt, Fernando
Palavras-chaveBreast Neoplasms
Cadherins
Carcinoma
Female
Humans
Immunohistochemistry
Phenotype
Receptor, ErbB-2
Vimentin
Basal-like breast cancer
P-cadherin
CK14
Data2010
EditoraUniversidad de Murcia
RevistaHistology and Histopathology
Resumo(s)Introduction: The most suitable immunohistochemical criterion to identify basal-like breast carcinomas (BLBC), a molecular subgroup of breast cancer associated with poor prognosis, is the triple negative phenotype along with CK5 and/or EGFR immunoreactivity. However, several putative basal markers have been suggested as alternatives to identify BLBC with more accuracy. Experimental Design: The expression of CK5, EGFR, P-cadherin, CK14, Vimentin and p63 were evaluated in 462 invasive breast carcinomas to determine their sensitivity and specificity for BLBC identification. Results: P-cadherin and CK5 showed higher sensitivity values, while EGFR, Vimentin and CK14 were the most specific markers. The combination of CK5 with P-cadherin, Vimentin or CK14 proved to be a reliable option for distinguishing the basal phenotype, compared to the “gold standard” pair CK5/EGFR. Furthermore, P-cadherin was still able to recognize a large number of putative BLBC among the “unclassified” group (ER-/PR-/HER2-/CK5-/EGFR-). Conclusions: P-cadherin, Vimentin and CK14 can recognize BLBC already identified in triple negative/ CK5 and/or EGFR+ tumors, and due to P-cadherin sensitivity for BLBC identification this marker can reliably recruit a large number of breast carcinomas with basal phenotype among immunohistochemistry triple negative/ CK5 and/or EGFR - pool of tumors. Although they need GEP validation, our results can introduce the idea of these markers as additional options in the daily workup of breast pathology laboratories to identify BLBC.
TipoArtigo
URIhttps://hdl.handle.net/1822/67559
DOI10.14670/HH-25.963
ISSN0213-3911
e-ISSN1699-5848
Arbitragem científicayes
AcessoAcesso restrito autor
Aparece nas coleções:ICVS - Artigos em revistas internacionais / Papers in international journals

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
SousaB.etal20101artigobarbara.pdf
Acesso restrito!
472,74 kBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID